Subscribe To

Price Alert Latest News Economic Calendar News

AVGR / Ground-Breaking Clinical Data from INSIGHT Trial Presented at VIVA

Study Outcomes Demonstrate Safety and Efficacy of Pantheris for Treatment of In-Stent Restenosis REDWOOD CITY, CA / ACCESSWIRE / October 7, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that clinical data from the INSIGHT study were presented during the Late-Breaking Clinical Trials session at the VIVA (Vascular InterVentional Advances) conference in Las Vegas. The INSIGHT trial was designed to evaluate the safety and effectiveness of Avinger's Pantheris image-guided atherectomy system for treating in-stent restenosis (ISR) in lower extremity arteries. Read More

Demo Live Account See Partner Details

Content Topics

Ground

Breaking

Clinical

Data

From

Insight

Trial

Presented

Ground breaking

Stock

AVGR

Posted: Oct 7 2021, 08:45

Author Name: Accesswire

AVGR News

By Zacks Investment Research
October 26, 2023

Avinger (AVGR) Reports Q3 Loss, Lags Revenue Estimates

Avinger (AVGR) came out with a quarterly loss of $2.92 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to loss of $11.

By Accesswire
October 19, 2023

Avinger to Announce Third Quarter 2023 Results on October 26

REDWOOD CITY, CA / ACCESSWIRE / October 19, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only

By Zacks Investment Research
July 27, 2023

Avinger (AVGR) Reports Q2 Loss, Misses Revenue Estimates

Avinger (AVGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.9

By Seeking Alpha
May 10, 2023

Avinger, Inc. (AVGR) Q1 2023 Earnings Call Transcript

Avinger, Inc. (NASDAQ:AVGR ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Kreps – Darrow Associates Investor R

By Seeking Alpha
March 15, 2023

Avinger, Inc (AVGR) Q4 2022 Earnings Call Transcript

Avinger, Inc (NASDAQ:AVGR ) Q4 2022 Earnings Call March 15, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates Investor Relations Jef

By Seeking Alpha
November 13, 2022

Avinger, Inc (AVGR) Q3 2022 Earnings Call Transcript

Start Time: 16:30 January 1, 0000 4:50 PM ET Avinger, Inc (NASDAQ:AVGR ) Q3 2022 Earnings Conference Call November 09, 2022, 16:30 PM ET Company Parti

By Seeking Alpha
May 10, 2022

Avinger, Inc. (AVGR) CEO Jeffery M. Soinski on Q1 2022 - Earnings Call Transcript

Avinger, Inc. (NASDAQ:AVGR ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jeffery M. Soinski – Chief Executive Offi

By Zacks Investment Research
May 10, 2022

Avinger (AVGR) Reports Q1 Loss, Misses Revenue Estimates

Avinger (AVGR) delivered earnings and revenue surprises of -92.56% and 0.11%, respectively, for the quarter ended March 2022. Do the numbers hold clue

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.